http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008187549-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_246577044a5630f8a7038d7a05e75340 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0006 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| filingDate | 2007-02-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b95d9492af83866870e9c06c32e57a14 |
| publicationDate | 2008-08-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2008187549-A1 |
| titleOfInvention | Polyantigenic-based (multiple antigens) modi or set of methods for developing infertility vaccines |
| abstract | Said invention is a unique modi or set of immunological techniques/methods, by which to develop various types of infertility vaccines, primarily designed to reduce fertility or to produce infertility in animals and/or in humans. Said reduced fertility or infertility may be permanent or exists with variable duration. The immunological infertility responses, resulting from said uniquely developed vaccines (as affected/created by the proposed methodologies), may be superior to currently existing infertility vaccines {referenced, herein}, since they (the vaccines resulting from the proposed methods, herein) would contain a far greater diversity/variety of antigens; and are therefore, considered as polyantigenic vaccines, herein. A larger diversity/variety of antigens may better elicit a greater diversity/variety of endogenous antibodies. A greater variety of antibody types and antibody variable sites may enhance the infertility response. n Correspondingly, the proposed methods may result in infertility vaccines which affect greater numbers and types of memory cells. While currently existing infertility vaccines use individual or limited numbers of identified antigens to sperm, or to sex-related hormones, etc. Said proposed modi or set of methods are unique, not only because they are polyantigenic, but because of some of the specified antigenic sources employed, besides sperm, i.e., ova, gamete germinal cells, gamete precursor cells, male ejaculate, liquor folliculi, certain differentiated stem cells, etc. The proposed modi does not use isolated/identified sperm antigens, as is currently used in infertility vaccines. Heretofore, the proposed modi has not been proposed. n Because humans and many domesticated animals (cats, dogs, cattle, sheep, birds, etc.) are such out-bred species, in that they may possess a broad variety of gamete-based antigens, individual responsiveness to an immunologic vaccine which uses a single or highly limited number (one or two) of isolated/identified antigens, is apt to be ineffective. Limited antigen types may fail to adequately address the vaccine recipient's own gamete-based antigens. The use of the proposed polyantigenic modi may enhance vaccine efficacy by providing a greater diversity of antigens, and thereby affecting a broader spectrum of response antibodies, etc. |
| priorityDate | 2007-02-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 38.